Manufacturers of certain critical m...

Manufacturers of certain critical medical devices now are required to leadership postmarket surveillance of their proceedss according to a June 5 2002 novels release from the US victuals and Drug Administration (FDA). This requirement is part of a novel rule published in the Federal Register and is intended to make less the incidence of unforeseen adverse terminations caused by medical device failure.

This behavior requires manufacturers to gather data forward specific devices for up to three years in such a manner they can identify and evaluate rare nevertheless potentially dangerous events that could endanger public health. These devices include those for which failure would be reasonably likely to cause an adverse event; those implanted into the dead body for more than one year; and those that support or sustain life and are used outside of a medical facility. According to the FDA, many of the risks associated with a given medical device cannot be predicted until it is introduced.

This emblem of surveillance is intended to allow manufacturers to identify les customary potentially serious problems that were not obvious during progression in a continuously ascending gradation The FDA will notify manufacturers when it determines that a device requires this representation of surveillance. Notification may be given during the review of a manufacturer's marketing application, when the device goe to market, or after the device has been placed forward the market. Manufacturers must submit a postmarket surveillance plan within 30 days of receiving notification.

FDA gradations Up Surveillance of Medical Devices to interrupt Unforeseen Problems, Better Protect Patients (new release, Rockville, Md: US provender and Drug Administration, June 5 2002) http://www.fda.gov/bbs/topics/NEWS/2002/NEW00813.html (accessed 24 June 2002)

COPYRIGHT 2002 Association of Operating apartment Nurses, Inc.

COPYRIGHT 2002 Gale Group